S895
An Act to promote transparency and prevent price gouging of pharmaceutical drug prices
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed Senate
- Passed House
- To Governor
- Became Law
Bill overview
This bill aims to increase transparency in the pharmaceutical drug pricing system and prevent what is considered ‘price gouging.’ It seeks to require pharmaceutical manufacturers to disclose the factors that contribute to their drug prices, promoting greater public understanding of how these costs are determined. The bill also intends to establish a process for reviewing and potentially addressing excessive price increases for essential medications.
Key provisions
- Requires pharmaceutical manufacturers to report the research and development costs, manufacturing costs, and marketing expenses associated with their drugs.
- Establishes a process for reviewing proposed drug price increases to determine if they are considered ‘price gouging.’
- Mandates the Department of Public Health to create a public database of drug prices.
- Requires pharmaceutical companies to provide justification for significant price increases.
- Allows for the potential for state review and adjustment of drug prices in cases of extreme price gouging.
Who is affected
- Pharmaceutical manufacturers
- Patients
- The Massachusetts Department of Public Health
- Prescribers
Notable changes
- The bill introduces a mechanism for reviewing and potentially regulating drug prices, which is not currently present in Massachusetts law.
- Requires detailed reporting of costs associated with drug pricing, increasing transparency.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Mark C. Montigny
Cosponsor
Mark C. Montigny
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.
Bill S.895 194th (Current)
An Act to promote transparency and prevent price gouging of pharmaceutical drug prices
By Mr. Montigny, a petition (accompanied by bill, Senate, No. 895) of Mark C. Montigny for legislation to promote transparency and prevent price gouging of pharmaceutical drug prices. Health Care Financing.
View Text Print Preview Download PDF
Bill Information
Bill Information
Presenter: Mark C. Montigny
Tabs
Bill History Petitioners Primary Sponsor Summary
Bill History
Displaying 4 actions for Bill S.895
| Date | Branch | Action |
| 2/27/2025 | Senate | Referred to the committee on Health Care Financing |
| 2/27/2025 | House | House concurred |
| 5/22/2025 | Joint | Hearing scheduled for 06/02/2025 from 11:00 AM-03:00 PM in Gardner Auditorium |
| 6/16/2025 | Senate | Accompanied S868 |
Similar Bills
S.652 190th (2017 - 2018)
An Act to promote transparency and prevent price gouging of pharmaceutical drug prices
S.712 191st (2019 - 2020)
An Act to promote transparency and prevent price gouging of pharmaceutical drug prices
S.804 192nd (2021 - 2022)
An Act to promote transparency and prevent price gouging of pharmaceutical drug prices
S.783 193rd (2023 - 2024)
An Act to promote transparency and prevent price gouging of pharmaceutical drug prices
H.1606 194th (Current)
An Act relative to law enforcement access to prescription monitoring data
The information contained in this website is for general information purposes only. The General Court provides this information as a public service and while we endeavor to keep the data accurate and current to the best of our ability, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.